BACKGROUND: Chronic lung diseases such as asthma, COPD and pulmonary fibrosis are characterized by abnormal extracellular matrix (ECM) turnover. TGF-β is a key mediator stimulating ECM production by recruiting and activating lung fibroblasts and initiating their differentiation process into more active myofibroblasts. Glycogen synthase kinase-3 (GSK-3) regulates various intracellular signalling pathways; its role in TGF-β₁-induced myofibroblast differentiation is currently largely unknown. PURPOSE: To determine the contribution of GSK-3 signalling in TGF-β₁-induced myofibroblast differentiation. EXPERIMENTAL APPROACH: We used MRC5 human lung fibroblasts and primary pulmonary fibroblasts of individuals with and without COPD. Protein and mRNA expression were determined by immunoblotting and RT-PCR analysis respectively. RESULTS: Stimulation of MRC5 and primary human lung fibroblasts with TGF-β₁ resulted in time- and dose-dependent increases of α-sm-actin and fibronectin expression, indicative of myofibroblast differentiation. Pharmacological inhibition of GSK-3 by SB216763 dose-dependently attenuated TGF-β₁-induced expression of these myofibroblasts markers. Moreover, silencing of GSK-3 by siRNA or pharmacological inhibition by CT/CHIR99021 fully inhibited the TGF-β₁-induced expression of α-sm-actin and fibronectin. The effect of GSK-3 inhibition on α-sm-actin expression was similar in fibroblasts from individuals with and without COPD. Neither smad, NF-κB nor ERK1/2 were involved in the inhibitory actions of GSK-3 inhibition by SB126763 on myofibroblast differentiation. Rather, SB216763 increased the phosphorylation of CREB, which in its phosphorylated form acts as a functional antagonist of TGF-β/smad signalling. CONCLUSION AND IMPLICATION: We demonstrate that GSK-3 signalling regulates TGF-β₁-induced myofibroblast differentiation by regulating CREB phosphorylation. GSK-3 may constitute a useful target for treatment of chronic lung diseases.
BACKGROUND:Chronic lung diseases such as asthma, COPD and pulmonary fibrosis are characterized by abnormal extracellular matrix (ECM) turnover. TGF-β is a key mediator stimulating ECM production by recruiting and activating lung fibroblasts and initiating their differentiation process into more active myofibroblasts. Glycogen synthase kinase-3 (GSK-3) regulates various intracellular signalling pathways; its role in TGF-β₁-induced myofibroblast differentiation is currently largely unknown. PURPOSE: To determine the contribution of GSK-3 signalling in TGF-β₁-induced myofibroblast differentiation. EXPERIMENTAL APPROACH: We used MRC5 human lung fibroblasts and primary pulmonary fibroblasts of individuals with and without COPD. Protein and mRNA expression were determined by immunoblotting and RT-PCR analysis respectively. RESULTS: Stimulation of MRC5 and primary human lung fibroblasts with TGF-β₁ resulted in time- and dose-dependent increases of α-sm-actin and fibronectin expression, indicative of myofibroblast differentiation. Pharmacological inhibition of GSK-3 by SB216763 dose-dependently attenuated TGF-β₁-induced expression of these myofibroblasts markers. Moreover, silencing of GSK-3 by siRNA or pharmacological inhibition by CT/CHIR99021 fully inhibited the TGF-β₁-induced expression of α-sm-actin and fibronectin. The effect of GSK-3 inhibition on α-sm-actin expression was similar in fibroblasts from individuals with and without COPD. Neither smad, NF-κB nor ERK1/2 were involved in the inhibitory actions of GSK-3 inhibition by SB126763 on myofibroblast differentiation. Rather, SB216763 increased the phosphorylation of CREB, which in its phosphorylated form acts as a functional antagonist of TGF-β/smad signalling. CONCLUSION AND IMPLICATION: We demonstrate that GSK-3 signalling regulates TGF-β₁-induced myofibroblast differentiation by regulating CREB phosphorylation. GSK-3 may constitute a useful target for treatment of chronic lung diseases.
Authors: A Smolenski; C Bachmann; K Reinhard; P Hönig-Liedl; T Jarchau; H Hoschuetzky; U Walter Journal: J Biol Chem Date: 1998-08-07 Impact factor: 5.157
Authors: Hoeke A Baarsma; Herman Meurs; Andrew J Halayko; Mark H Menzen; Martina Schmidt; Huib A M Kerstjens; Reinoud Gosens Journal: Am J Physiol Lung Cell Mol Physiol Date: 2011-03-18 Impact factor: 5.464
Authors: Hoeke A Baarsma; Anita I R Spanjer; Gertruud Haitsma; Lilian H J M Engelbertink; Herman Meurs; Marnix R Jonker; Wim Timens; Dirkje S Postma; Huib A M Kerstjens; Reinoud Gosens Journal: PLoS One Date: 2011-09-30 Impact factor: 3.240
Authors: Ashley R Rackow; David J Nagel; Claire McCarthy; Jennifer Judge; Shannon Lacy; Margaret A T Freeberg; Thomas H Thatcher; R Matthew Kottmann; Patricia J Sime Journal: Eur Respir J Date: 2020-11-26 Impact factor: 16.671
Authors: Hoeke A Baarsma; Sophie Bos; Herman Meurs; Kim H Visser; Marieke Smit; Annemie M W J Schols; Ramon C Langen; Huib A M Kerstjens; Reinoud Gosens Journal: Respir Res Date: 2013-10-23
Authors: Travis Lear; Alison C McKelvey; Shristi Rajbhandari; Sarah R Dunn; Tiffany A Coon; William Connelly; Joe Y Zhao; Daniel J Kass; Yingze Zhang; Yuan Liu; Bill B Chen Journal: J Exp Med Date: 2016-05-09 Impact factor: 14.307
Authors: Mary Y Chang; Inkyung Kang; Michael Gale; Anne M Manicone; Michael G Kinsella; Kathleen R Braun; Tara Wigmosta; William C Parks; William A Altemeier; Thomas N Wight; Charles W Frevert Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-09-14 Impact factor: 5.464
Authors: Henna M Karvonen; Siri T Lehtonen; Terttu Harju; Raija T Sormunen; Elisa Lappi-Blanco; Johanna M Mäkinen; Kirsi Laitakari; Shirley Johnson; Riitta L Kaarteenaho Journal: Respir Res Date: 2013-08-11